Home
overview

With cancer a well publicised killer worldwide, the need is ever pressing for novel therapies to improve the prognosis.  Imaging techniques applied in oncology aid the diagnosis and monitoring of cancer, and as such can also be applied to the development of newer, more enhanced drugs.

SMi’s 5th annual conference on Imaging in Oncology aims to bring together industry experts in oncology imaging to discuss the applications of Exploratory Imaging and explore the regulatory, logistics and practicality challenges of imaging in Oncology.  This year's event aims to bring you in-depth information regarding both the clinical and preclinical options available in oncology imaging right now. Don't miss the opportunity to learn from the expertise of those at the forefront of the oncology imaging field.

                            

GAIN an insight into the newest developments in oncology imaging
IDENTIFY key areas for the application of novel imaging techniques
REVIEW alternative imaging techniques in use in oncology
EXAMINE regulatory challenges and how these can be overcome
HEAR from top industry experts within the oncology imaging field                
                                     
If you are a Vice President, Executive, Director, Project manager, Researcher or Scientist working for pharmaceutical or biotech companies in the following areas:
  • Discovery Medicine
  • Cancer & Infection
  • Biomedical Imaging
  • Pharmacology
  • Clinical Technology
  • Clinical Diagnostics
  • Oncology
  • Diagnostic Imaging
  • Oncology Imaging
  • Molecular Imaging
  • Specialized Therapeutics
  • Neuroimaging and neurology
  • Oncology technology
  • Clinical strategy
This conference is an unmissable opportunity to raise the profile of your company amongst the market leaders in this area.
Delegates at last years conference included representatives from:
  • Abbott
  • Amgen
  • AstraZeneca
  • Bayer Schering
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Genentech
  • GlaxoSmithKline
  • Johnson & Johnson
  • MedImmune
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi-Aventis
  • Schering
  • UCB Celltech
For speaker opportunities please contact Rachel Francis on +44 (0)20 7827 6056 or email rfrancis@smi-online.co.uk
For sponsorship opportunities please contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Matthew Silva

Matthew Silva, Head of Imaging Sciences, Millennium Pharmaceuticals

9:10 EXPLORATORY IMAGING IN ONCOLOGY TRIALS

Haren Rupani

Haren Rupani, Global Head, Oncology Imaging, Novartis

  • What is exploratory imaging?
  • Efforts and costs required
  • What clinical questions can be answered and does it justify the cost
  • Challenges with imaging when conducting multinational, multi-centre trials
  • 9:50 INDEPENDENT REVIEW FOR ONCOLOGY CLINICAL TRIALS: LESSONS LEARNED

    Karoline Meurer

    Karoline Meurer, Managing Director, RadPharm

  • What is ICR (Independent Central Review) and why do you need it?
  • Discordance between local and central interpretations
  • Operational considerations
  • Overcoming challenges (Protocol requirements)
  • 10:30 RADIOTRACER DEVELOPMENT AND IN VIVO IMAGING WITH PET

    Tony Gee

    Tony Gee, Director, PET & Radiotracer Development, GlaxoSmithKline

  • Radiotracer design
  • Impact of design on in vivo signal and scan data
  • Examples
  • 11:10 Morning Coffee

    11:30 THE DEVELOPMENT OF A STANDARDISED MOLECULAR IMAGING TOOLKIT FOR ONCOLOGY

    Matthew Miller

    Matthew Miller, Principal Medical Physicist, GE Healthcare

  • Development of molecular imaging PET agents to monitor disease progression and response to therapy
  • FASTlab - an automated PET radiochemistry synthesis platform with multi-tracer capability
  • 12:10 PET AND FUNCTIONAL IMAGING IN ONCOLOGY

    Iman El-Hariry

    Iman El-Hariry, Senior Director, Oncology Medicines Centre, GlaxoSmithkline

  • Background on PET and DCE-MRI in head and neck cancer
  • Level of existing evidence
  • Case history
  • Future directions
  • 12:50 Networking Lunch

    13:50 PANEL DISCUSSION

  • EORTC have revised their original 2000 guidelines
  • New version to be released January 2009
  • Discuss the implications for pharma and CRO's
  • Haren Rupani

    Haren Rupani, Global Head, Oncology Imaging, Novartis

    Kevin Brindle

    Kevin Brindle, Professor of Biomedical Magnetic Resonance, University of Cambridge and Cancer Research UK

    Volker Dicken

    Volker Dicken, Lead Scientist, Oncological Imaging, Fraunhofer MEVIS

    14:30 CAN PET SUPPORT SCHEDULING OF VASCULAR TARGETING AND CYTOTOXIC CANCER TREATMENTS IN CLINICAL DEVELOPMENT?

    Barbara Koetz

    Barbara Koetz, Associate Director, TA, Oncology, Eisai

  • PET perfusion imaging
  • Effects of vascular targeting agents on normal and tumor tissue
  • Imaging tissue pharmacokinetics of 5-fluorouracil
  • Relationship between perfusion and tissue exposure to chemotherapy
  • 15:10 Afternoon Tea

    15:40 AUTOMATED IMAGE ANALYSIS IN HISTOPATHOLOGY: A VALUABLE TOOL IN MEDICAL DIAGNOSTICS

    Elton Rexhepaj

    Elton Rexhepaj, Informatics Officer, OncoMark

  • Gap between discovery and validation following -omic studies
  • The IHC surrogate concept
  • Use of automated image analysis to fast-track biomarker assessment
  • Case study in breast cancer
  • 16:20 ASSAY DEVELOPMENT FOR PRECLINICAL AND TRANSLATIONAL IMAGING

    Matthew Silva

    Matthew Silva, Head of Imaging Sciences, Millennium Pharmaceuticals

  • Role and prioritization of preclinical and translational imaging biomarkers
  • Qualification of preclinical assays for novel therapeutics
  • Examples and expectations
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Ken Miles

    Ken Miles, Prof, Imaging, Brighton & Sussex Medical School

    9:10 TRANSLATIONAL IMAGING IN ONCOLOGY

    Raymond Josephsson

    Raymond Josephsson, Head Translational Imaging, F Hoffmann - La Roche

  • The Concept of translation applied to oncology imaging
  • Successful examples of bridging from Preclinical oncology to the clinics
  • Challenges, pitfalls and potential strategies of translational imaging in Oncology
  • 9:50 KEYNOTE ADDRESS: MOLECULAR IMAGING APPROACHES IN DRUG DEVELOPMENT

    Susanta Sarkar

    Susanta Sarkar, Director, Clinical Imaging, GlaxoSmithKline

  • Challenges associated with the development of targeted drugs
  • Molecular imaging approaches to help address the issues
  • 10:30 Morning Coffee

    11:00 INTEGRATING HIGH-CONTENT IN VITRO PHENOTYPIC ASSAYS WITH FUNCTIONAL IN VITRO AND IN VIVO IMAGING APPROACHES TO IMPROVE CLINICAL PREDICTIVITY

    Neil Carragher

    Neil Carragher, Associate Principal Scientist, AstraZeneca

  • Development of high-content phenotypic assays across panels of physiologically relevant cancer cell lines
  • Development of more complex "higher dimensional" 3D and kinetic in vitro models of tumor progression
  • Application of fluorescent in vivo imaging approaches to calibrate predictivity of in vitro models
  • Incorporation of in silico modelling and advanced statistics to extrapolate findings from experimental in vitro, in vivo and ex-vivo imaging studies into the clinic
  • 11:40 DETECTING TUMOUR RESPONSES TO TREATMENT USING MAGNETIC RESONANCE IMAGING

    Kevin Brindle

    Kevin Brindle, Professor of Biomedical Magnetic Resonance, University of Cambridge and Cancer Research UK

  • Drug development
  • Treatment selection
  • Detecting tumour cell death
  • Imaging tumour metabolism using hyperpolarised magnetic resonance imaging
  • 12:20 Networking Lunch

    13:50 FUNCTIONAL IMAGING IN ANGIOGENESIS CLINICAL TRIALS

    Ken Miles

    Ken Miles, Prof, Imaging, Brighton & Sussex Medical School

  • Techniques for imaging angiogenesis, PET, CT & MR
  • Case studies of angiogenesis imaging in cancer trials
  • Combining angiogenesis imaging with other imaging biomarkers
  • 14:30 QUANTITATIVE IMAGING

    Volker Dicken

    Volker Dicken, Lead Scientist, Oncological Imaging, Fraunhofer MEVIS

  • RECIST versus volumetric measurements of tumor size on CT data
  • Quantification in nuclear medicine
  • Advantage of CT for large scale clinical trials
  • Results on the analysis of lung tumor movement and volume in 4D imaging prior to radiation therapy
  • 15:10 Chairman’s Closing Remarks

    15:30 Afternoon Tea and Close of Conference

    +

    Workshops

    Technological Advancement in Oncology Translational Imaging
    Workshop

    Technological Advancement in Oncology Translational Imaging

    Copthorne Tara Hotel
    28th April 2009
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.